Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Human IL-29 (IFN lambda-1) (Carrier-Free) Recombinant Protein
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
34-8298-64
产品规格
Expression System
E. coli
分类
Recombinant
类型
Protein
偶联物
形式
Lyophilized
保存条件
-20°C
运输条件
Dry ice
产品详细信息
Description: IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low levels of costimulatory molecules. Moreover, these cells can specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cells with contact-dependent suppressive activity.
Applications Reported: This protein has been demonstrated to induce STAT2 phosphorylation.
Applications Tested: Recombinant human IL-29 (IFN lambda 1) is biologically active and can induce STAT2 phosphorylation.
Source: E. coli (amino acids Pro23-Thr178; accession # NP_742152.1).
Bioactivity: This protein has been demonstrated to induce STAT2 phosphorylation.
Endotoxin: Less than 0.1 ng/ug cytokine as determined by the LAL assay. Purity: >98% as determined by SDS-PAGE and HPLC.
Molecular Weight: 19.8 kDa.
Storage and handling: For best recovery, quick spin vial prior to opening. Use in sterile environment. Reconstitute in water to a concentration of less than 0.5 - 1.0 mg/mL. Do not vortex. Store lyophilized protein at less than or equal to -20°C. Reconstituted protein solution can be stored with carrier protein (e.g., 0.1% BSA) at less than or equal to -20°C.
靶标信息
IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low levels of costimulatory molecules. Moreover, these cells can specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cells with contact-dependent suppressive activity.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
